1 to 9 of 17 results

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market


The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Improved symptom control and quality of life among greatest unmet needs in metastatic-resistant prostate cancer therapy


Symptom control and quality of life is one of the factors the most influences surveyed US and European…

BayerCometriqEuropeExelixisJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyorteronelPharmaceuticalTakeda PharmaceuticalsXofigoZytiga

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers


A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches


The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

Regulatory briefs on vortioxetine, canagliflozin/metformin combo and Rescula


Takeda Global Research & Development Center, a unit of Japanese drug giant Takeda Pharma's (TYO: 4502),…

BrintellixcanagliflozinDiabetesJanssenJohnson & JohnsonLundbeckmetforminNeurologicalNorth AmericaOphthalmicsPharmaceuticalRegulationResculaSucampoTakeda Pharmaceuticalsvortioxetine

Multiple myeloma drug market forecast to reach $7.2 billion in 2021


The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

CHMP positive on first gene therapy, Glybera; and more opinions


Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

Affymax and Janssen Biotech enter $13 million peginesatide patent settlement


US biotech firm Affymax (Nasdaq: AFFY) says it has reached a global settlement agreement with Janssen…

AffymaxBiotechnologyJanssen PharmaceuticaJohnson & JohnsonOncologyPatentspeginesatidePharmaceuticalTakeda Pharmaceuticals

1 to 9 of 17 results

Back to top